crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
alminox "dak" 500 mg + 100 mg tyggetabletter
orifarm healthcare a/s - aluminiumaminoacetat, hydrat, magnesiumhydroxid, tungt - tyggetabletter - 500 mg + 100 mg
link 150 mg/ml oral suspension
actavis group ptc ehf. - aluminiumhydroxid-magnesiumcarbonat co-prÆcipitat gel - oral suspension - 150 mg/ml
magnesia "dak" 500 mg filmovertrukne tabletter
orifarm healthcare a/s - magnesiumhydroxid - filmovertrukne tabletter - 500 mg
magnesia "medic" 500 mg filmovertrukne tabletter
viatris aps - magnesiumhydroxid - filmovertrukne tabletter - 500 mg
novaluzid 110+40 mg/ml oral suspension
meda as - aluminiumhydroxid, magnesiumoxid - oral suspension - 110+40 mg/ml
rayaldee 30 mikrogram depotkapsler, bløde
vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram
alfacalcidol "alternova" 0,25 mikrogram kapsler, bløde
alternova a/s - alfacalcidol - kapsler, bløde - 0,25 mikrogram
alfacalcidol "alternova" 0,5 mikrogram kapsler, bløde
alternova a/s - alfacalcidol - kapsler, bløde - 0,5 mikrogram
alfacalcidol "alternova" 1 mikrogram kapsler, bløde
alternova a/s - alfacalcidol - kapsler, bløde - 1 mikrogram